Loading
A phase 1/2 trial of Penpulimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C is a phase 1/2 interventional study registered as NCT06821503 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 72 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-12. Interventions recorded: LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound) and Gemcitabine hydrochloride for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Penpulimab, Sino Biopharmaceutical (Chia Tai Tianqing), Immune checkpoint inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/